NOVOLOG MIX 50/50 Drug Profile

Summary for Tradename: NOVOLOG MIX 50/50

High Confidence Patents:	33
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for NOVOLOG MIX 50/50

Recent Clinical Trials for NOVOLOG MIX 50/50

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Xentria, Inc.	PHASE1
Amphastar Pharmaceuticals, Inc.	Phase 2/Phase 3
The Cleveland Clinic	Phase 4

See all NOVOLOG MIX 50/50 clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLOG MIX 50/50 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLOG MIX 50/50 Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	10,376,652	2037-02-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	11,097,063	2039-01-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NOVOLOG MIX 50/50 Derived from Patent Text Search

No patents found based on company disclosures

International Patents for NOVOLOG MIX 50/50

Country	Patent Number	Estimated Expiration
Australia	6820500
World Intellectual Property Organization (WIPO)	2006079481
Spain	2001624
Greece	3015031

Supplementary Protection Certificates for NOVOLOG MIX 50/50

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB00/027	United Kingdom		PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
10199011	Germany		PRODUCT NAME: KRISTALLE, ENTHALTEND ASP B28 HUMAN-INSULIN UND PROTAMIN; REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801
SPC/GB99/045	United Kingdom		SPC/GB99/045: 20060829, EXPIRES: 20110828

Market Dynamics and Financial Trajectory for NovoLog Mix 50/50

Last updated: April 11, 2026

What is NovoLog Mix 50/50?

NovoLog Mix 50/50 is a premixed insulin formulation developed by Novo Nordisk. It contains 50% insulin aspart (rapid-acting insulin) and 50% insulin aspart protamine (intermediate-acting insulin). Approved by regulators such as the FDA in 2002, it provides dual-action control for blood glucose levels in people with diabetes.

Market Overview

Insulin Segment Growth

The global insulin market was valued at approximately USD 42 billion in 2022 and is projected to reach USD 78 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 13.4% (Research and Markets, 2022). This growth is driven by increasing diabetes prevalence, aging populations, and rising awareness.

Product Portfolio of Novo Nordisk

Novo Nordisk dominates the insulin market, holding over 50% of global insulin sales in 2022. Its portfolio includes basal insulins (Levemir, Tresiba), premixed insulins (NovoLog Mix, especially 70/30 and 50/50), and GLP-1 receptor agonists.

Competitive Products

Key competitors include Eli Lilly, Sanofi, and Humulin. Sanofi's Humalog Mix 75/25 and Humulin 70/30 are primary rivals to NovoLog Mix formulations. Lilly's Humalog Mix 75/25 competes directly as a rapid/short-acting premixed insulin.

Market Penetration and Patient Preference

Premixed insulins like NovoLog Mix 50/50 cater to patients seeking simplified regimens, combining rapid and intermediate insulin. Their convenience appeals mainly to type 2 diabetes users, especially those managing insulin therapy at home.

Financial Trajectory

Sales Performance

In 2022, NovoLog accounted for roughly USD 2.3 billion in sales, with premixed insulins contributing approximately 40% of this segment. Premium formulations like NovoLog Mix 50/50 are steady but face pressure from biosimilars and newer insulin types.

Revenue Trends

Sales for premixed insulins have shown modest growth amid rising adoption of basal-baseline analogs and insulin pumps. NovoLog Mix 50/50’s sales are projected to grow at a CAGR of 3-5% over the next five years, influenced by increased insulin therapy adoption and higher prevalence of diabetes globally. However, patent expirations in some markets may introduce biosimilar competition, impacting margins.

Pricing and Reimbursement Landscape

Pricing pressures stem from healthcare payers seeking cost-containment. In the U.S., the average wholesale price (AWP) for NovoLog Mix 50/50 was approximately USD 250 per vial in 2022, with net prices decreasing due to rebates and discounts. Internationally, pricing varies significantly across regions with cost-sensitive markets experiencing more substantial reductions.

Impact of Biosimilars

Lilly and Biocon have developed biosimilar versions of insulin analogs, though regulatory hurdles and market acceptance slow penetration. Price reductions of 15-25% are expected when biosimilars gain traction, potentially eroding revenue streams.

Market Drivers and Challenges

Drivers

• Rising global diabetes prevalence: An estimated 537 million adults with diabetes in 2021, projected to increase to 643 million by 2030 (IDF, 2021).
• Preference for fixed-dose regimens among specific patient segments.
• Aging populations increasing insulin therapy demand.

Challenges

• Competition from basal-bolus regimens and non-insulin therapies such as SGLT2 inhibitors and GLP-1 receptor agonists.
• Regulatory delays and cost pressures.
• Limited innovation in premixed insulin formulations compared to newer insulin analogs.

Strategic Outlook

• Pipeline Development: Novo Nordisk is investing in simpler formulations and novel delivery devices to sustain growth.
• Market Expansion: Focus on emerging markets, where the insulin market is less saturated.
• Biosimilar Engagement: Preparing for biosimilar entry through strategic pricing and increased patient support programs.

Key Financial Metrics

Metric	2022	2027 (Projected)	Notes
Global insulin market value	USD 42B	USD 78B	13.4% CAGR
NovoLog sales (total)	USD 2.3B	USD 3.0B	Moderate growth, led by premixed segment
Premixed insulin segment share	40%	45%	Expected slight increase due to patient preference
Price per vial	USD 250	USD 230	Price erosions from biosimilar competition

Summary

NovoLog Mix 50/50 maintains steady sales owing to its convenience and established presence. Its growth is constrained by patent expirations and competitive pressures but benefits from the global increase in diabetes prevalence. Strategic investments and market expansion are key to sustaining its financial trajectory.

Key Takeaways

• The insulin market is expanding, with premixed insulins like NovoLog Mix 50/50 representing a significant segment.
• Revenue for NovoLog Mix 50/50 is projected to grow at approximately 3-5% annually until 2027, barring major biosimilar price erosion.
• Price pressures and biosimilar entries are primary risks, especially in cost-sensitive markets.
• Growth opportunities exist in emerging markets and through product differentiation, such as delivery devices.
• Competition from newer insulin formulations and non-insulin treatments may impact long-term market share.

FAQs

What factors influence the sales of NovoLog Mix 50/50?

Prevalence of diabetes, patient preference for simplified regimens, cost and reimbursement policies, and competitive biosimilar entries.

How does biosimilar entry affect NovoLog Mix 50/50?

Biosimilars can reduce prices by 15-25%, leading to revenue erosion and increased price competition.

What are growth prospects for premixed insulins?

Limited by the rise of basal-basal analogs and non-insulin therapies but supported by demand in specific patient populations seeking simplified regimens.

Which regions are key for market expansion?

Emerging markets such as China, India, and Latin America, where insulin access is growing and cost sensitivities are high.

How is Novo Nordisk addressing biosimilar competition?

Investing in product innovation, delivery technologies, and expanding access through pricing strategies and patient support programs.

---

References

[1] Research and Markets. (2022). Global Insulin Market: Trends, Opportunities and Forecast till 2027.
[2] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.